Dosage Charts Calculator Blends & Stacks Learn Blog Peptides
Open Calculator
Blog  ›  Tesamorelin vs MK-677: Research Dosing Compared Simply

Tesamorelin vs MK-677: Research Dosing Compared Simply

Jun 11, 2026 4 min Growth Hormone
TL;DR
Tesamorelin is an injectable peptide with FDA-approved roots, studied mainly for fat loss in HIV patients. MK-677 is an oral, non-peptide pill studied for muscle wasting and growth. Both boost growth hormone, but their dosing, safety signals, and evidence bases differ in important ways.

Two Paths to the Same Destination

Your body releases growth hormone (GH) in pulses. Both Tesamorelin and MK-677 are designed to encourage those pulses. But that's roughly where the similarities end.

Think of GH-releasing hormone (GHRH) as the body's "go" signal for growth hormone. Tesamorelin mimics that signal directly. MK-677 takes a different road — it mimics a hunger hormone called ghrelin, which also triggers GH release. Same destination, very different routes.[4]

What Is Tesamorelin?

Tesamorelin is a synthetic analogue of GHRH — basically a lab-made copy of the peptide your hypothalamus already produces.[2] It's given as a subcutaneous injection (a small shot under the skin). The FDA approved it under the brand name Egrifta for a specific condition: excess belly fat in HIV patients with lipodystrophy, a fat-distribution disorder caused by some HIV medications.[2]

Because it has that approved use, Tesamorelin has a more defined clinical research trail than many peptides. Researchers studying it in other contexts — like body composition or sports medicine — are building on that foundation.[5]

What Is MK-677?

MK-677 (also called Ibutamoren) is not a peptide at all — it's a small-molecule drug taken by mouth. It mimics ghrelin, the "hunger hormone," and binds to the same receptor. That binding tells the pituitary gland to pump out more GH and IGF-1 (a growth factor that does much of GH's work in tissues).[1]

One early human study showed that 25 mg of oral MK-677 per day for 7 days reversed diet-induced muscle protein loss. Nitrogen balance — a marker of whether you're gaining or losing protein — flipped from negative to positive.[1] That's a meaningful finding for researchers studying muscle wasting.

Animal studies have added nuance. In rats given MK-677 for 6 weeks, GH spiked initially but the effect faded. The brain appeared to compensate by raising somatostatin, a natural GH brake. Body growth did not increase despite the early GH bump.[6]

Research Dosing at a Glance

  • Tesamorelin (human research): Typically 2 mg injected subcutaneously once daily, as used in approved HIV-lipodystrophy protocols.[2]
  • MK-677 (human research): 25 mg orally once daily was the dose used in the landmark nitrogen-balance study.[1]
  • Route matters: Tesamorelin must be injected; MK-677 is swallowed. Injection delivers the peptide intact; oral dosing is more convenient but the biology differs.[4]
  • Duration signals differ: MK-677 animal data suggest potential desensitization over weeks.[6] Tesamorelin studies ran for months in clinical settings.[2]

Want to compare these numbers side by side? Our calculator can help you explore research dosing ranges in context.

Safety Signals Worth Knowing

No compound is without flags. A 2025 case report described a man in his early 30s who developed liver enzyme elevation (transaminitis) after two months of MK-677 use. His liver tests normalized after stopping the supplement.[3] This is a single case, not proof of widespread risk, but it's a data point researchers and readers should know about.

Tesamorelin, by contrast, has not been linked to liver enzyme elevations or clinically apparent liver injury in its research record.[2] Common concerns with GH-pathway compounds in general include fluid retention, changes in blood sugar, and increased appetite — all worth tracking in any research protocol.

How to Choose What to Read About

Neither compound is a magic bullet, and the research community is still filling in major gaps. A 2026 sports medicine review noted that for most peptides — including Tesamorelin in orthopaedic contexts — information on optimal dosing, frequency, and duration simply doesn't exist yet.[5] Another 2026 review echoed that preclinical promise hasn't yet translated into robust clinical trial data.[4]

So how do you pick which research to follow? A simple framework:

  • If you're interested in fat metabolism research: Tesamorelin has the deeper approved-use evidence base.[2]
  • If you're interested in muscle-wasting or anti-catabolic research: MK-677's oral convenience and early human data make it a frequent subject of study.[1]
  • If you want the full dosing picture: Visit the dedicated Tesamorelin chart or MK-677 chart for structured research summaries.

This content is for educational and research-reading purposes only. It is not medical advice. Always consult a qualified healthcare professional before making any health decisions.

Sources

  1. MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism. — The Journal of clinical endocrinology and metabolism, 1998. PMID 9467534.
  2. Tesamorelin. — , 2012. PMID 31644039.
  3. Hepatotoxicity induced by MK-677. — BMJ case reports, 2025. PMID 40675653.
  4. Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. — Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews, 2026. PMID 41490200.
  5. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. — The American journal of sports medicine, 2026. PMID 41476424.
  6. Effect of the Orally Active Growth Hormone Secretagogue MK-677 on Somatic Growth in Rats. — Yonsei medical journal, 2018. PMID 30450851.
See the dosage chart — Tesamorelin
A growth-hormone-releasing hormone analog studied for visceral fat reduction.
Tesamorelin

FAQ

What is the main difference between Tesamorelin and MK-677?
Tesamorelin is an injectable peptide that directly mimics the body's own growth hormone-releasing hormone. MK-677 is an oral pill that mimics ghrelin, a hunger hormone, to indirectly trigger GH release. Both raise GH levels, but through different mechanisms, different routes of administration, and with different clinical research histories behind them.[1][2]
What dose of MK-677 was used in human research studies?
The most cited early human study used 25 mg of MK-677 taken orally once daily for 7 days. In that trial, participants who were calorically restricted showed improved nitrogen balance — a sign of reduced protein breakdown — compared to placebo. Researchers noted the compound was generally well tolerated at that dose in the short term.[1]
Is MK-677 safe to use?
Research is still developing. Known side effects include increased appetite, fluid retention, and muscle discomfort. A 2025 case report documented liver enzyme elevation in one user after two months of MK-677 supplementation, which resolved after stopping use. This is a single case, but it highlights that safety monitoring matters in any research context.[3]
Does Tesamorelin have any FDA-approved use?
Yes. Tesamorelin is FDA-approved under the brand name Egrifta for treating excess abdominal fat (lipodystrophy) in HIV-positive patients. That approved indication gives it a more established clinical research profile than many other peptides studied for body composition. It has not been linked to liver injury in its documented research record.[2]
For research and educational use only. Not medical advice.